Status Epilepticus is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Status Epilepticus have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Status Epilepticus compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Status Epilepticus overview
Status epilepticus is an emergency neurological condition where seizures last for more than five minutes; historically, it was diagnosed for seizures longer than than 30 minutes. Patients with this condition do not regain consciousness between seizures, which can lead to death. Hence, it requires immediate emergency evaluation and management. Seizures can be convulsive or non-convulsive, and are most commonly observed in pediatric patients as febrile seizures. It can be caused by pre-existing seizures in patients on irregular medications, age, hypoxia, drug toxicity, genetics, head trauma, or CNS infections like meningitis. Neuroimaging studies and laboratory investigations are done for the diagnosis. CT scan, EEG, and MRI are the most common procedures. Management is primarily to abort the seizures by using emergency or rescue medications, providing supportive care with oxygen therapy, and anti-epileptic drugs.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Status Epilepticus, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
